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Background: The tissue-specific Unigene Sets derived from more than one million expressed sequence tags (ESTs)
in the NCBI, GenBank database offers a platform for identifying significantly and differentially expressed
tissue-specific genes by in-silico methods. Digital differential display (DDD) rapidly creates transcription profiles
based on EST comparisons and numerically calculates, as a fraction of the pool of ESTs, the relative sequence
abundance of known and novel genes. However, the process of identifying the most likely tissue for a specific
disease in which to search for candidate genes from the pool of differentially expressed genes remains difficult.
Therefore, we have used ‘Gene Ontology semantic similarity score’ to measure the GO similarity between gene
products of lung tissue-specific candidate genes from control (normal) and disease (cancer) sets. This semantic
similarity score matrix based on hierarchical clustering represents in the form of a dendrogram. The dendrogram
cluster stability was assessed by multiple bootstrapping. Multiple bootstrapping also computes a p-value for each
cluster and corrects the bias of the bootstrap probability.
Results: Subsequent hierarchical clustering by the multiple bootstrapping method (α = 0.95) identified seven
clusters. The comparative, as well as subtractive, approach revealed a set of 38 biomarkers comprising four distinct
lung cancer signature biomarker clusters (panel 1–4). Further gene enrichment analysis of the four panels revealed
that each panel represents a set of lung cancer linked metastasis diagnostic biomarkers (panel 1), chemotherapy/
drug resistance biomarkers (panel 2), hypoxia regulated biomarkers (panel 3) and lung extra cellular matrix
biomarkers (panel 4).
Conclusions: Expression analysis reveals that hypoxia induced lung cancer related biomarkers (panel 3), HIF and its
modulating proteins (TGM2, CSNK1A1, CTNNA1, NAMPT/Visfatin, TNFRSF1A, ETS1, SRC-1, FN1, APLP2, DMBT1/SAG,
AIB1 and AZIN1) are significantly down regulated. All down regulated genes in this panel were highly up regulated
in most other types of cancers. These panels of proteins may represent signature biomarkers for lung cancer and
will aid in lung cancer diagnosis and disease monitoring as well as in the prediction of responses to therapeutics.
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Gene expression analysis in the post genomic era
through high throughput genomic studies led to identifi-
cation of enormous candidate genes related to patho-
physiological conditions or altered signal transduction.
One such freely available high throughput database is
‘Unigene’ (http://www.ncbi.nlm.nih.gov/Unigene/). The
Unigene libraries of interest with varying treatment con-
ditions can be digitally ‘pooled’ and compared to control
vs. treatment using Digital Differential Display (DDD). It
enables the identification of numerical differences in
transcript frequency between the individual or pooled
Unigene libraries from the various treatment conditions
and multiple cDNA libraries. The frequency of each dif-
ferentially expressed transcripts and their fold change
from the pooled libraries have been calculated using
Fisher Exact Test. The prioritisation of DDD identifica-
tion from differentially expressed candidate genes strictly
used relative change in the frequency value and its fold
change. Apart from DDD, many web tools are freely
available to prioritise candidate genes based on the rela-
tive change in gene expression profile [1,2]. The priori-
tisation of each tool differs due to their different
computational approaches [3]. But the process of identi-
fying the most likely tissue specific disease candidate
genes from the pool of differentially expressed genes
remained difficult [1].
Recent advances in the systems biology have shown
promising results in the elucidation of potential biomar-
kers of phenotype and clinical relevance, particularly in
cancer research sphere [4-6]. These studies were per-
formed using the predictive integration of gene expres-
sion data. Different predictive integration strategies have
been developed and were used to study the biological in-
formation from public repositories [4-8]. Amongst such
strategies, gene products that are biologically and func-
tionally related would maintain similarity, both in their
expression profiles and in the Gene Ontology (GO) an-
notation [9]. The integration of gene expression data
and standardised descriptions of the biological function
of gene products were used for the search of candidate
prognostic biomarkers and therapeutic targets [10-12].
These studies demonstrated that the measure of func-
tional similarity based GO annotations between query
genes and the genes of interest can be applied as a com-
plementary predictive feature to characterise gene ex-
pression profile. So, we have applied this integrative
computational approach to characterise a tissue specific
biological data from DDD.
We hypothesised that tissue specific differentially
expressed genes can be functionally characterised using
their GO semantic similarity score with normal tissue
specific genes (query genes). The query genes, in this
study, were normal lung tissue specific genes from theTissue-Specific Genes Database (TiSGeD). The genes of
interest were candidate lung cancer genes from DDD
[13,14]. Surprisingly, this approach successfully distin-
guished 38 signature biomarkers for lung cancer. Thus
this suggests that, in principle, this integrated method-
ology can offer a complementary predictive capability
for detecting tissue specific signature biomarkers from
the tissue specific differentially expressed data. These tis-
sue specific signature biomarkers may be candidate
prognostic biomarkers and therapeutic targets for lung
cancer.
Methods
Selection of Human Lung Tissue specific query genes
The normal lung tissue specific genes were collected
from TiSGeD (Tissue-specific gene database; http://
bioinf.xmu.edu.cn/databases/TiSGeD/index.html).
Human adult lung tissue related genes with tissue speci-
ficity measure score (SPM) ≥ 0.9 (represents high tissue
specificity) were considered. The lung tissue specific
“Mouse” and “developmental” genes were omitted.
Collection of Lung Tissue specific differentially Expressed
Candidate Genes using DDD
DDD comparisons were made at various tissue stages to
elucidate the selective differential expression levels of
human lung tissue specific genes for normal (Case 1)
and cancerous (Case 2) conditions. In Case 1, the Nor-
mal lung tissues (11 tissue libraries) were considered as
a ‘Reference’ samples and the remaining normal human
tissues (251 tissue libraries) were ‘Query’ samples. In
Case 2, the Normal lung tissues (11 tissue libraries) were
considered as ‘Reference’ samples and the cancerous
human lung tissues (8 tissue libraries) were ‘Query’ sam-
ples. These comparisons were designed systematically so
as to identify altered Gene expression of varying treat-
ment conditions of ‘Reference’ and ‘Query’ samples.
These pair wise comparisons resulted in a relative abun-
dance of ESTs among the contrasting cDNA libraries of
digitally ‘pooled’ contracts from Unigene Database.
GO-based similarity assessment
Org.Hs.eg.db package in R-program was used for the
computation of Semantic similarity score while the GO-
based similarity score was computed based on the three
orthogonal gene ontologies generated for Molecular
Function (MF), Cellular Component (CC) and Biological
process (BP). GOSemSim of R-program was used to cal-
culate semantic similarity between the GO terms and
the gene products. In this study, GO terms derived from
human annotations were used for calculations. The esti-
mation of between-term similarity was based on the
Wang semantic similarity measure [12]. Aggregation of
between-term similarities was done with the highest
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aggregates maximum between-gene similarity values [9].
Given a pair of gene products, gi and gj, annotated to a
set of GO terms, the GO-driven similarity, SIM (gi, gj),
is calculated by aggregating the maximum interest simi-
larity values as follows:
Sim gi; gjð Þ ¼
X
1≤i≤m





max Sim gj1ð Þ gið Þð Þð Þ
#
=mþ n
where, two sets of GO terms gi = {gi1, gi2, . . .. . .. . .. . ...,
gim} & gj = {gj1, gj2, . . .. . .. . .. . .. . ., gjn} as query and
reference sequence. Method max calculates the max-
imum semantic similarity score over given pairs of GO
terms between these two sets, while average calculates
the average semantic similarity score over a given pairs
of GO terms. The hierarchical clustering of tissue spe-
cific, differentially expressed genes in relation with a
normal lung tissue is shown in a Dendrogram. In the
colour code of heat map, red represents a low semantic
similarity below the median level, whereas, the green
represents a high semantic similarity above the median
level.
Clustering analysis
The clustering analysis was carried out by the program
pvclust [15]. It is an add-on package for a statistical soft-
ware R to perform the bootstrap analysis of clustering
and also to assess the uncertainty in hierarchical cluster
analysis. The package calculates the approximately un-
biased (AU) and bootstrap probability (BP) p-values for
each cluster. Stability of the clustering was accessed at
95% probability (α = 0.95).
Results
DDD based prioritisation of lung cancer genes
In order to find the lung tissue specific differentially
expressed genes, two Unigene pools (A and B) were con-
structed (See Additional file 1). For analysis, in the
DDD1, we employed the UniGene pool (A) representing
39 human normal tissues excluding normal lung tissue
and UniGene pool (B) representing 11 counterpart lung
normal tissues were employed for analysis (Table 1).
Similarly, in DDD2, UniGene pool (A) representing 8
human lung tumours and UniGene pool (B) representing
11 counterpart lung normal tissues were employed
(Table 1). The fold change of normal lung (DDD1) and
lung carcinoma candidate genes (DDD2) were calculated
based on transcript frequency values. The candidate
genes with an expression of at least 2-fold difference
were taken into analysis. In DDD1, amongst the total of519 differentially expressed genes 268 genes were up-
regulated (≥2-fold) and 234 genes were down-regulated
(≥2-fold). In DDD2, amongst the total of 203 differen-
tially expressed candidate genes, 147 genes (≥2-fold) in-
cluding 33 unknown were up-regulated (≥2-fold) and 55
genes were down-regulated (≥2-fold). Comparison of
DDD1 with DDD2 has revealed that in total 76 genes
from DDD1 were differentially expressed in DDD2 (See
Additional file 2). From the literature survey, amongst
the 76 genes, 18 of them were found to be commonly
expressed in all types of cancerous conditions (See
Additional file 3) [16]. Excluding these 18 from the 76,
the remaining 58 genes were predicted as the lung tissue
specific tumour genes (See Additional file 2). The mo-
lecular functions of these 58 genes were found to be
involved in broad range of cellular functions with major-
ity of the genes playing many different roles like struc-
tural, extracellular and intracellular functions. This
subtractive approach eliminated most of the commonly
expressing genes; for example, housekeeping genes. This
approach has also helped to eliminate genes expressing
in more than 10 cancerous conditions (See Additional
file 4).
Prediction of Lung tissue specific tumour genes by
Semantic similarity score based clustering
To identify lung tissue specific clusters from the 202
genes from DDD2 cancerous condition, firstly they were
subjected to similarity clustering analysis using the 47
lung tissue specific genes from TiSGeD (See Additional
file 5). Before the semantic similarity clustering analysis,
the Unigene ID were converted into Entrez ID. During
this process, the 202 genes of DDD2 reduced to 145 and
the 47 lung tissue specific genes of TiSGeD were
reduced to 28 due to gene duplication. Using GOSem-
Sim package, the similarity correlation matrix was con-
structed between the 145 predicted lung specific
differentially expressed cancer genes from DDD2 and 28
genes from TiSGeD. The differential expression levels of
these clustered genes were depicted in the form of a
Heat Map (Figure 1). The similarity correlation matrix
produced seven gene clusters at 95% confidence level,
using the pvclust program (Figure 2). The clusters 1–4
have 14 genes and the clusters 5, 6 and 7 have 36, 74
and 14 genes respectively.
In the ID conversions from Unigene to Entrez, the 58
lung tissue specific tumour genes were reduced to 38
genes (Table 2). These 38 genes were matched with the
7 clusters. This38 genes formed four panels with the
corresponding cluster 4, 5, 6 and 7 respectively. The
panels 1–4 contained 2, 9, 21 and 6 genes respectively.
This leads to identification of the lung tissue specific
clusters of the normal lung tissue specific genes differen-
tially regulated in lung cancer condition.





dbEST identification number Respective Number of ESTs
1 Adipose 2 10983, 16445 8299, 1646
2 Adrenal
gland
4 6791, 6792, 16377, 18302 4582, 1425, 2756, 10026
3 Tongue 4 12982, 18362, 18389, 18479 1116, 7730, 23564, 7420
4 Bladder 1 18307 8220
5 Blood 6 7037, 7038, 8975, 11923, 6824, 9724 1524, 1721, 4215, 6553, 7241, 9352
6 Bone 3 1124, 821, 16433 6209, 1337, 2615
7 Bone
marrow
8 6975, 6976, 15949, 15950, 16412, 931, 10409, 10410 2459, 3424, 1379, 2707, 3623, 5336, 1798, 5231
8 Brain 36 1749, 16376, 16390, 18317, 18318, 18352, 18353, 18415,
18466, 14591, 14592, 186, 17380, 742, 16380, 18310, 18311,
16382, 16383, 18322, 1918, 5655, 6811, 6812, 8570, 19377,
14298, 13711, 13053, 536, 7209, 16384, 18319
1600, 1361, 13592, 2579, 15152, 43177, 24735, 23791,
6112, 31569, 15839, 1461, 1334, 18126, 5838, 4298, 3364,
41751, 40272, 2802, 3192, 16612, 7369, 8197, 2790, 3145,
19115, 44785, 1609, 7033, 3931, 4897, 5194, 2565, 25752
9 Eye 26 13915, 17747, 7316, 7315, 10273, 10287, 13901, 19465,
10274, 10281, 10280, 10288, 10279, 10284, 19471, 10285,
10286, 12093, 302, 303, 433, 10966, 10282, 10283, 16572,
13902
3739, 4253, 1836, 1294, 4005, 3543, 2785, 1334, 1595,
1479, 1115, 6010, 1469, 6719, 3043, 8344, 1199, 7816,
9190, 1732, 2174, 4531, 6279, 1185, 6097, 2946
10 Heart 8 15951, 16399, 18354, 18410, 16421, 18503, 16379, 16381 5307, 3284, 2667, 8670, 4000, 8502, 7220, 4698
11 Stomach 12 10299, 10301, 10302, 10305, 10306, 10310, 10311, 10324,
10325, 18488, 18529, 16432
1793, 2409, 1453, 2790, 1692, 1984, 6125, 5913, 1422,
8604, 2574, 3137
12 Testis 5 1752, 16441, 18476, 18517, 19376 6624, 2983, 46964, 44057, 40315
13 Thalamus 3 16437, 18348, 18349 3154, 29651, 23010
14 Thymus 6 16440, 18518, 18519, 18520, 13049, 18375 2365, 1044, 31967, 37541, 3477, 15983
15 Thyroid 3 889, 16408, 7004 1357, 4827, 3342
16 Breast 4 894, 895, 18305, 18475 1786, 6346, 2538, 8256
17 Cartilage 2 8936, 8940 4310, 3858
18 Cervix 2 18425, 18506 2674, 2619
19 Ear 2 371, 18222 12666, 3396
20 Intestine 13 840, 841, 842, 882, 16385, 18350, 18489, 16387, 16400,
17427, 18473, 16425, 18486
1499, 1704, 1759, 11996, 1817, 8191, 2619, 1351, 5536,
8199, 16855, 3403, 2545
21 Epidermis 4 20865, 21612, 7269, 21098 1627, 13186, 10681, 1135
22 Lung 11 10395, 16406, 16413, 16438, 18355, 18363, 18521, 10398,
11912, 18522, 18537
12545, 2448, 6839, 3327, 2565, 16156, 2677, 11510,
15695, 32590, 19278
23 Liver 11 1365, 12531, 12532, 12535, 12549, 12550, 13859, 16392,
18416, 18525, 18893




3 6982, 16420, 16436 4561, 3502, 3371
25 Lymph 8 2709, 2710, 2711, 3718, 3719, 3720, 10312, 8613 3434, 3963, 1000, 9867, 1556, 1828, 7590, 1949
26 Teeth 1 12639 1576
27 Medulla 1 9725 9919
28 Muscle 4 530, 16391, 45, 18501 4271, 2154, 2485, 8276
29 Ovary 7 887, 6998, 18421, 18527, 5444, 12637, 12638 2341, 3678, 2300, 2543, 10294, 1050, 1031
30 Nose 2 358, 13908 1702, 24528
31 Placenta 14 13037, 16442, 507, 740, 6999, 10403, 10404, 10405,
10424, 10425, 16422, 17682, 18468, 18484, 13000
11885, 3501, 1370, 1172, 20941, 1862, 1166, 4260, 4517,
1271, 1529, 1032, 16852, 15843, 7344
32 Pancreas 6 16423, 422, 16960, 8840, 3884, 9821 4308, 1799, 13791, 60665, 1234, 17183
33 Prostate 8 888, 17392, 18469, 19880, 16424, 924, 928 1014, 1283, 16483, 41945, 2355, 7609, 1114, 1051
34 Uterus 6 1753, 16443, 18523, 18531, 18544, 12528 1645, 5121, 30124, 2486, 19168, 3510
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Table 1 Different tissue specific Unigene libraries employed in DDD (Continued)
37 Kidney 7 16393, 16395, 16410, 18374, 18377, 18524, 16429 5486, 5150, 3565, 17079, 2561, 15730, 1170
37 Pituitary 4 6828, 6829, 13019, 13737 3481, 1444, 7327, 1677
38 immune
cells
6 1317, 17555, 17556, 8892, 12072, 12798 11447, 15272, 13685, 6112, 9223, 4548
39 Hair 4 21096, 21100, 21099, 21101 1269, 1288, 1298, 1543
40 Alimentary
canal
2 18496, 18418 8371, 2586
41 Cancerous
lung
8 1533, 10419, 537, 914, 14132, 14133, 14134, 14135 1377, 4401, 4173, 1850, 4365, 2121, 2847, 1560
Differentially expressed normal lung tissue specific genes (DDD1) were identified from UniGene libraries representing 39 human normal tissues (251 libraries,
1903301 ESTs, S. No. 1–21, 23–40) and counterpart normal lung tissue (11 libraries, 125630 ESTs, S. No. 22 only). Differentially expressed lung tissue specific genes
(DDD2) were identified from UniGene libraries representing lung cancer libraries (8 libraries, 22694 ESTs, S. No. 41 only) and counterpart normal lung tissue
(11 libraries, 125630 ESTs, S. No. 22 only).
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panel as given below.
Analysis of Cluster 4 / Panel 1
The cluster 4 had two-lung cancer related genes ubiqui-
tin thiolesterase (UCHL1) and Lactotransferrin (LTF). In
the normal lung (DDD1 data), UCHL1 was down-
regulated and LTF was up-regulated (Table 2). This was
reversed during the lung cancer condition where
UCHL1 up-regulated and the LTF highly down-
regulated (Table 2). These two proteins were found to be
important in the cancer progression. UCH-L1 up-regula-
tion promoted prostate cancer metastasis through
epithelial-to-mesenchymal transition (EMT) induction
and LTF expression decreased in lung prostate cancer
progression [17,18]. Both of them were co-expressed in
almost six different lung adenocarcinoma cell lines, as
evident by mSigDB. This suggested that UCH-L1 and
LTF could be novel diagnostic and therapeutic targets
for lung cancer metastasis diagnostic markers.Analysis of Cluster 5 / Panel 2
The cluster 5 was playing the common functional role of
immune response and complement activation. The down-
regulated RPSA, RPL9, TMSB4X and TUBA1B in normal
lung (DDD1) were significantly up-regulated in lung cancer
(DDD2) (Table 1). The analysis resulted that all these up
regulated genes played the role of tumour cell resistance to
the anti-cancer agents. In gastric cancers, the up-regulation
of RPSA/LRP contributed to drug resistance via hypoxia-
inducible-factor dependent mechanism [19]. Similarly, there
was a link between the TMSB4X and TUBA1B and the
anti-cancer drug resistance to the drug Paclitaxel (PTX)
observed in the cervical and breast/ovarian cancers respect-
ively [20,21].
In this cluster, NT5C2, API5, CPN, PRKAR1A and
COPB1 were fully down-regulated in lung cancer(Table 1). The down regulation of NT5C3 altered the
tumour cell sensitivity to cytidine based anti-cancer
drugs [22]. The anti-apoptosis gene API5 down-
regulation linked to increase in the survival and resist-
ance cancer cells to chemotherapy [23]. To our know-
ledge, the major copper carrying protein CPN
(ceruloplasmin) down regulation link to chemotherapy/
drug resistance is not yet studied. But increased level of
copper in lewis lung carcinoma cells were related with
the development of multi drug resistance [24]. The
PRKAR1A down-regulation also linked to multidrug-
resistant (MDR) in colon carcinoma cells [25]. The
COPB1 was an essential component for the coatomer
formation [26]. These coatomers were involved in the
drug trafficking pathways and endocytic drug delivery
[27]. So, it was expected that the down-regulation of
COPB1 might have a role in the chemotherapy which
needs to be taken up and studied. We are surprised to
find that all these results suggest that the cluster 5 func-
tionally represents a panel of chemotherapy/drug resist-
ance related lung cancer biomarkers.
Analysis of Cluster 6 / Panel 3
In cluster 6, the upregulated FTL (65 fold in our study)
and ALDOA (7 fold in our study) were regulated by hyp-
oxia inducible factor (HIF) during lung cancer [28-31].
The COL1A1 (23 fold in our study) and GAPDH (11 fold
in our study) were regulated by hypoxia [32-34]. IGKC
(8 fold in our study) up-regulated in lung cancer patients
but no literature data was available for its interaction
either with HIF or hypoxia [35]. The HIF, TGM2,
CSNK1A1, CSNK2A1, CTNNA1, NAMPT)/Visfatin,
TNFRSF1A, ETS1 and SRC-1 were down-regulated and
proposed as the biomarkers for lung cancer. We found all
of them to be interacting with the HIF in cancerous con-
dition [36-45]. The down- regulated FN1 and APLP2
showed hypoxia dependent differential regulation [46-48].
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Figure 1 Go semantic similarity score between the set of normal lung tissue specific genes from TiSGeD (28-horizontal, x-axis) and the
differentially expressed lung cancer genes from DDD2 (145-vertical, y-axis). The intensity of the color corresponds to the magnitude of the
similarity. Red represents low semantic similarity below the median level whereas the green represents high semantic similarity above the
median level.
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induced HIF-1 to transactivate SAG and the induced
SAG then promoted HIF-1alpha ubiquitination and deg-
radation [49]. The FBJ/c-Jun/AP-1 interacted with HIF
during hypoxia that controlled the transcriptionalregulation of the Cyr61 gene in retinal vascular endothe-
lial cells [50]. The role of AIB1/SRC-3/NCoA during hyp-
oxia condition were exhibited by controlling the
expression levels of HIF induced erythropoietin (EPO)






























































































































































































































































































































































































































































































































































































































































































Figure 2 Average correlation distances with hierarchical clustering based on GO semantic similarity score matrix calculated between
normal lung tissue specific genes from TiSGed and differentially expressed lung cancer gene from DDD2. Values in red represent AU
(Approximately unbiased) p-value and green represents BP (Bootstrap probability) Clusters with AU larger than 95% are highlighted by red
rectangle boxes. AU p-value, which is computed by multiscale bootstrap resampling, is a better approximation to unbiased p-value than BP value
computer by normal bootstrap resampling.
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were down-regulated and were lacking direct experimen-
tal evidence to support their regulation with HIF or hyp-
oxia during cancer. The following literature analysis
suggests their possible regulations either with HIF or
hypoxia. The AZIN1 was an inhibitor for the antizyme
and both were highly regulated in human cancers and
antizyme induced HIF, during increased cellular redox
potential [51-53]. The TICAM2 physically bridged toll
like receptor-4 (TLR4) with TICAM1 and the TLR4 par-
tially regulated by the HIF during adenocarcinoma
[54,55].
All these results suggest that the cluster 6 represents
the panel of either HIF or Hypoxia related lung cancer
biomarkers.
Analysis of Cluster 7 / Panel 4
In the Cluster 7, there were seven lung biomarkers,
mostly encoding for lung tissue specific extra cellular
matrix proteins. The epigenetic analysis using Methy-
cancer database (http://methycancer.genomics.org.cn)
revealed that amongst the seven, KIAA1324, NET1,
NTN3, RPL10 and TFPI2 were epigenetically regulated
through DNA methylation. In the remaining two,
SFTPA1 was epigenetically regulated [56-58]. However,
the experimental evidence was lacking the epigenetic
related data for CRISP3. However, the Gene carddatabase analysis of CRISP3 showed that the CRISP3
orthlogous gene C-type lectin domain family 18 member
A (CLEC18A) epigenetically regulated through DNA
methylation (http://www.genecards.org). All these results
show that the cluster 7 represented the panel of epigen-
etically regulated lung cancer specific extra cellular
matrix biomarkers.
Discussion
UniGene database using the DDD tool provides us a
computational approach to study and understand the
lung tissue specific gene expression levels in both disease
and normal conditions [59]. Studying their differential
expression in disease state (lung cancer) will provide a
clue about lung cancer specific candidate genes. How-
ever, the candidate identification of the DDD method is
relying on the EST frequencies based fold change calcu-
lation. In DDD2, the 203 differentially expressed candi-
date genes (≥2-fold) ranking / prioritisation only based
upon fold change did not account for the tissue specific
variability of the genes in disease conditions (eg: bio-
marker identification). To include the tissue specific
variability in DDD2 prioritisation, the normal lung tissue
specific genes from DDD1 were compared. This ap-
proach eliminated most of the house keeping genes from
the analysis (gene list reduced from 202 to 76). Further,
we detected genes expression selectively altered in the
Table 2 Lung cancer signature biomarker clusters
Clustering of lung tissue specific cancer Biomarkers DDD1 DDD2
Panel / Cluster
of Biomarker

















Panel 1 / Cluster 4 Lung cancer metastasis
diagnostic markers
UCHL1 0 0.0002 - 0 0.0011 +
LTF 0.0224 0.0018 +12.44 0.0224 0.0002 -112
Panel 2 / Cluster 5 Chemotherapy/ drug
resistance related lung
cancer biomarkers
TUBA1B 0 0.0002 - 0 0.0013 +
RPSA 0.0001 0.0004 -4 0.0001 0.0027 +27
RPL9 0.0002 0.0006 -3 0.0002 0.002 +10
TMSB4X 0.0004 0.001 -2.5 0.0004 0.0016 +4
COPB1 0.0007 0.0002 +3.5 0.0007 0 -
API5 0.0007 0.0003 +2.3 0.0007 0 -
NT5C2 0.0008 0.0003 +2.6 0.0008 0 -
CPN 0.0009 0.0001 +9 0.0009 0 -
PRKAR1A 0.0017 0.0006 +2.83 0.0017 0 -
Panel 3 / Cluster 6 Hypoxia related lung
cancer biomarkers
FTL 0.0001 0.0011 -11 0.0001 0.0065 +65
COL1A2 0.0001 0.0006 -6 0.0001 0.0023 +23
GAPDH 0.0001 0.001 -10 0.0001 0.0011 +11
IGKC 0.0002 0.0009 -4.5 0.0002 0.0016 +8
ALDOA 0.0002 0.0006 -3 0.0002 0.0014 +7
COL1A1 0.0001 0.0004 -4 0.0001 0.0009 +9
FN1 0.0025 0.0012 +2.08 0.0025 0.0007 -3.57
TGM2 0.0026 0.0008 +3.25 0.0026 0.0007 -3.71
FOS 0.0015 0.0007 +2.14 0.0015 0.0002 -7.5
CTNNA1 0.0034 0.0008 +4.25 0.0034 0.0003 -11.33
FOSB 0.0024 0.0003 +8 0.0024 0.0002 -12
APLP2 0.0109 0.0044 +2.47 0.0109 0.0008 -13.63
NCOA4 0.0016 0.0005 +3.2 0.0016 0.0001 -16
HIF1A 0.0011 0.0004 +2.75 0.0011 0 -
AZIN1 0.001 0.0005 +2 0.001 0 -
EHF 0.001 0.0001 +10 0.001 0 -
TICAM2 0.001 0.0003 +3.33 0.001 0 -
NAMPT 0.0008 0.0002 +4 0.0008 0 -
TNFRSF1A 0.0008 0.0004 +2 0.0008 0 -
DMBT1 0.0008 0.0001 +8 0.0008 0 -
CSNK1A1 0.0007 0.0003 +2.33 0.0007 0 -
Panel 4 / Cluster 7 Lung cancer specific
extra cellular matrix
biomarkers
TFPI2 0 0.0004 - 0 0.002 +
RPL10 0.0001 0.0007 -7 0.0001 0.0014 +14
SFTPA1 0.0004 0 + 0.0001 0.0011 +11
KIAA1324 0.0013 0.0002 +6.5 0.0013 0 -
CRISP3 0.0009 0.0001 +9 0.0009 0 -
NET1 0.0007 0.0002 +3.5 0.0007 0 -
Note: (−) represents down regulation and (+) represents up regulation. Except SFTPA1, remaining all the up regulated genes in normal condition observed to be
down regulated in cancerous condition and vice versa.
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expressed differentially in more than five tumours (gene
list reduced from 76 to 58) (See Additional file 2). Al-
most all of them have a documented role in the lung
cancer (http://www.megabionet.org/bio/hlung). So, these
subtractive approaches successfully increase the prob-
ability of identifying the lung cancer specific probable
candidate biomarkers.
The semantic similarity scores amongst the GO terms
and the subsequent hierarchical clustering were calculated
using the freely available R-software for lung tissue specific
candidate genes from normal and cancer conditions. The
analysis of members of individual genes from each cluster
revealed the functional significance of each cluster. Out of
the seven clusters, our approach identified four function-
ally important clusters. The four clusters represented me-
tastasis diagnostic markers, chemotherapy/drug resistance
related biomarkers, and HIF or Hypoxia induced biomar-
kers and epigenetically regulated extra cellular matrix bio-
markers for lung cancer. This suggests that, especially for
lungs tissues, the semantic similarity score amongst GO
terms between normal and diseases condition from the
same tissue can prioritise biomarkers. But, further study is
necessary to extend our hypothesis to other tissues. This
subtractive approach integrated with semantic similarity
score among GO terms can offer a predictive capability
for detecting tissue specific signature biomarkers from the
tissue specific differentially expressed data. This approach
is also complementary to the network based biomarker
prediction approach [60,61]. Our study is one more ex-
ample of demonstrating the utility of the Digital differen-
tial expression technique.
Our study suggests that amongst the 4 panels, HIF or
Hypoxia induced lung cancer biomarkers panel (panel 3)
is the most important cluster. Because, in other clusters,
most of the identified lung cancer biomarkers follow the
same expression pattern (either up or down) in other
types cancers like breast, ovarian, cervical etc. However,
in our study and literature, the expression pattern of
genes down regulated in cluster 6 / panel 3 is distinct
from almost all types of other cancers. In panel 3, the
expression pattern of the HIF and its modulating pro-
teins are completely different when compared to most of
the other types of cancers. For example, in most of the
cancerous conditions the HIF level is up-regulated [62].
This up-regulation is expected in cancers due to the
acute hypoxic condition exhibited during cancer. In con-
trast, in lung cancer, the HIF level is completely down-
regulated (Table 1).
Therefore, it is evident from our study that the HIF
down regulation also affect the expression level of the
other HIF modulating lung cancer biomarkers. All the
down-regulated genes, in this Panel 3 showed their sig-
nificant up-regulation in most of many types of cancers(TGM2 [63,64], CSNK1A1 [65], CTNNA1 [66],
NAMPT/Visfatin [67], TNFRSF1A [68], ETS1 [41], SRC-
1 [69], FN1 [70], APLP2 [71], DMBT1/SAG [64], AIB1
[72], AZIN1 [72]). Our study further shows that this
down-regulation is more than five folds when compared
to the normal lungs tissue (Table 1). This fold change
level suggests that this fold change seems to be more
than enough to detect them in the patient sample.
Therefore, this panel of down regulating HIF / hypoxia
regulated lung cancer biomarker can help to distinguish
lung cancer from other types of cancers.
The identified 38 signature lung cancer specific bio-
markers can help to increase the sensitivity and selectiv-
ity for early diagnosis of lung cancer.
Conclusion
We could demonstrate that our approach readily pre-
dicted lung tissue specific cancer biomarkers from digital
differentially expressed lung cancer tissue specific genes.
The procedure can easily adapt for the prediction of tis-
sue specific biomarkers from the tissue specific differen-
tially expressed genes. It is necessary to explore the
extent to which the proposed approach can be inte-
grated with the prediction of tissue specific biomarkers
from tissue specific microarray datasets.
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